All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 179 of 206 pages ‹ First < 177 178 179 180 181 > Last ›
HSL5717
Thai seminar on drug promotion
Essential Drugs Monitor 19945
HSL5718
Ahmad SR.
Lilly’s misleading promotion
Lancet 1994;344:464-465
HSL5719
Bardelay D.
French doctors report on sales representatives’ visits
Essential Drugs Monitor 199421
HSL5720
Basar L.
Practical considerations when evaluating direct-to-consumer advertising as a marketing strategy for prescription medications
Drug Information Journal 1994;28:461-470
HSL5721
Beales JH.
Economic analysis and the regulation of pharmaceutical advertising
Seaton Hall Law Review 1994;24:1370-1398
HSL5722
Beary JF.
More conflicts of interest: review articles sponsored by the pharmaceutical industry
JAMA 1994;272:1254
HSL5723
Beazley GP.
Size of names in drug ads
Canadian Medical Association Journal 1994;151:1113
HSL5724
Bell TR.
Bromocriptine and drug information
Lancet 1994;343:297
HSL5725
Brennan TA.
Buying editorials
New England Journal of Medicine 1994;331:673-675
HSL5726
Physicians and the pharmaceutical industry (update 1994)
Canadian Medical Association Journal 1994;150:256A-256C
HSL5728
Chetley A.
Generic embarrassment
Lancet 1994;343:1089-1090
HSL5729
Chirac P.
Control of drug advertising in France: a poor example
Prescrire International 1994;3:(13):145-147
HSL5730
Chirac P.
Drug advertising must be more strictly controlled
Prescrire International 1994;3:(13):160
HSL5731
Chren M-M.
Independent investigators and for-profit companies: guidelines for biomedical scientists considering funding by industry
Archives of Dermatology 1994;130:432-437
HSL5732
Chren M-M, Landefeld CS.
Pharmaceutical promotion and physician requests to hospital formularies
JAMA 1994;272:355
HSL5897
Coney S.
NZ review of drug prescribing and advertising
Lancet 1994;344:1353-1354
HSL5899
Danby FW.
Interacting with the pharmaceutical industry
Canadian Medical Association Journal 1994;151:732
HSL5901
Durbin RL.
Appetite stimulant claim deleted from label—response
Canadian Family Physician 1994;40:22
HSL5902
Engle R.
The impact of a single-advertiser publication on physicians’ perceptions and expected perscribing behavior
Journal of Pharmaceutical Marketing & Management 1994;8:(1):37-54
HSL5904
Fassett WE.
Professional organizations and healthcare industry support: ethical conflict. Commentary
Cambridge Quarterly of Healthcare Ethics 1994;3:253-255
HSL5905
Forrest DM, Ruedy J.
Proposed guidelines
Annals of the Royal College of Physicians and Surgeons of Canada 1994;27:46-47
HSL5907
Gaither CA, Bagozzi RP, Kirking DM, Ascione FJ.
Factors related to physicians’ attitudes and beliefs toward drug information sources
Drug Information Journal 1994;28:817-827
HSL5908
Gardner L.
Professional organizations and healthcare industry support: ethical conflict. Commentary
Cambridge Quarterly of Healthcare Ethics 1994;3:247-253
HSL5909
Gesensway D.
Dealing with the new breed of detailers: the drug industry wants to be your ‘essential medical educator’
ACP Observer 1994;14:(8):8-9
HSL6028
Guyatt G.
Interacting with the pharmaceutical industry
Canadian Medical Association Journal 1994;151:732
HSL6029
Guyatt , G .
Relations with the pharmaceutical industry
Canadian Medical Association Journal 1994;151:415
HSL6030
Harvey K, Black F.
Prescribing rationally, not fashionably
Essential Drugs Monitor 1994
HSL6031
Hazlet TK, Sullivan SD.
Professional organizations and healthcare industry support: ethical conflict?
Camb Q Healthc Ethics 1994 Spr;3:(2):236-44
HSL6033
Huston P.
Advertising in medical journals
Canadian Medical Association Journal 1994;151:7
HSL6034
Advertising in medical journals
Canadian Medical Association Journal 1994;150:27
HSL6035
Advertising in medical journals and the use of supplements
Canadian Medical Association Journal 1994;151:527
HSL6036
Jacoby J.
Misleading research on the subject of misleading advertising: the Wilkes et al. investigation of pharmaceutical advertising in leading medical journals
Food and Drug Law Journal 1994;49:21-33
HSL6037
Kassirer JP, Angell M.
Conflicts of interest and the Journal’s policies
New England Journal of Medicine 1994;330:504
HSL6148
Leisinger KM.
Professional organizations and healthcare industry support: ethical conflict. Commentary
Cambridge Quarterly of Healthcare Ethics 1994;3:244-247
HSL6151
Lexchin J.
Canadian marketing codes: how well are they controlling pharmaceutical promotion?
Int J Health Serv 1994;24:(1):91-104
HSL6155
Mansfield PR.
MaLAM: encouraging trustworthy drug promotion
Essential Drugs Monitor 1994;(17):6
HSL6432
Matalia N.
Journal advertising works! Three studies say so!
Medical Marketing & Media 1994;29:(5):12-14, 16, 18-20
HSL6433
May JR.
Professional organizations and healthcare industry support: ethical conflict. Commentary
Cambridge Quarterly of Healthcare Ethics 1994;3:255-256
HSL6434
McArthur R.
The hitch-hickers’ guide to promotional drug literature
Essential Drugs Monitor 1994;17:24
HSL6435
McCarthy M.
Bromocriptine not for lactation suppression
Lancet 1994;344:602
HSL6439
Odegaard PR.
Relations with the pharmaceutical industry
Canadian Medical Association Journal 1994;151:415
HSL6443
Pelton LE, Strutton D, Smith MC.
Pharmaceutical promotion to physicians: a synthesis model of persuasive communications
Journal of Social and Administrative Pharmacy 1994;11:161-172
HSL6444
Pines WL.
Some major issues in direct-to-consumer advertising
Food and Drug Law Journal 1994;49:589-592
HSL6446
Rachlis M, Kushner C.
Strong medicine: how to save Canada’s health care system
Toronto: HarperCollins Publishers Ltd. 1994
HSL6447
Ragg M.
RACP on doctors’ links with drug industry
Lancet 1994;343:909
HSL6448
Ramsay S.
UK drugs code tightened
Lancet 1994;343:1217
HSL6451
Rothman KJ.
Conflicts of interest and the Journal’s policies
New England Journal of Medicine 1994;330:503-504
HSL6452
Rubin PH.
Are pharmaceutical ads deceptive?
Food and Drug Law Journal 1994;49:7-19
HSL6457
Short B.
Advertising or research?
Canadian Medical Association Journal 1994;150:11
HSL6458
Slotnick HB, Raszkowski RR, Jensen CE, Wentz DK, Kuntz TA.
Physician preferences in CME including insights into education versus promotion
Journal of Continuing Education in the Health Professions 1994;14:173-186
HSL6460
Squires BP.
Advertising and integrity
Canadian Medical Association Journal 1994;151:407
HSL6461
Squires BP.
Advertising and supplements
Canadian Medical Association Journal 1994;151:503
HSL6468
Sussman S.
Drug advertising corrupts journals
BMJ 1994;308:1301
http://www.bmj.com/cgi/content/full/308/6939/1301
HSL6470
Teehan M.
Guidelines for phase IV clinical trials
Canadian Journal of Psychiatry 1994;39:629-630
HSL6471
Thomas L.
Inadvertment placement of advertisements
Medical Journal of Australia 1994;160:727-728
HSL6472
Thompson C.
Genentech suspends marketing practices
Lancet 1994;344:1146
HSL6474
van Maaren PJM, van Mil JWF, Hardon AP, Haaijer-Ruskamp FM, Dukes MNG
Dutch drugs in developing countries
Groningen: Styx Publications 1994
HSL6475
Van STAA.
A mutual bond: pharmaceutical representatives and doctors in the Philippines
Essential Drugs Monitor 1994;(17):22-23
HSL6477
Walsh CJ.
FDA efforts to control the flow of information at pharmaceutical industry-sponsored medical education programs: a regulatory overdose
Seaton Hall Law Review 1994;24:1325-1369
HSL6478
Whelan AM, Nagpal S, Burge F.
Drug information resources in a family medicine residency training program
Canadian Pharmaceutical Journal 1994;127:(9):39, 41-43, 46
HSL6480
Witt MD, Gostin LO.
More conflicts of interest: review articles sponsored by the pharmaceutical industry
JAMA 1994;272:1254
HSL6481
Wolever TMS.
Rejection policy questioned
Canadian Medical Association Journal 1994;151:737
HSL6482
Woosley RL.
A prescription for better prescriptions.
Issues Sci Technol 1994 Spr;10:(3):59-66
HSL6483
Writer W, Desmond R.
Proposed guidelines
Annals of the Royal College of Physicians and Surgeons of Canada 1994;27:46
HSL6488
Marketing self-regulation strengthened in Australia
Health Horizons 1994;(22):22
www.ifpma.rog/hhhs/welcome.htm
HSL6493
Knowledge campaign update
PMAC News 1994;2
www.canadapharma.org
HSL6494
Selected annotated bibliography on essential drugs
Geneva: World Health Organization 1994
HSL6495
WHO Ethical Criteria for medicinal drug promotion—off the shelf and into the legislatures
Amsterdam: Health Action International 1994
www.haiweb.org
HSL6496
The industry/physician interface . . . converging or diverging perspectives?
Montreal: PSL Reports 1994
HSL6497
Deutsch N.
Better drug information with less hype?
Physician’s Management Manuals 1994;18:(6):33-34
HSL6513
Boots claims “Prothiaden sets the standard” and in one study “96% had responded to treatment and 94% did not experience intolerable side effects”
MaLAM Australian News 1994;2:(1):1-2
HSL6517
Roche Bactrim for respiratory tract infections?
MaLAM Australian News 1994;2:(2):1
HSL6518
Wellcome’s promotion of Septrin
MaLAM Australian News 1994;2:(2):1-2
HSL6525
IFPMA and the industry’s role in medical information
Health Horizons 1994;(23):2
www.ifpma.rog/hhhs/welcome.htm
HSL6526
IFPMA: revised marketing code adopted
Health Horizons 1994;(23):14
www.ifpma.rog/hhhs/welcome.htm
HSL6527
Continuing health education is focus of marketing code amendments
PMAC News 1994;1-2
HSL6549
Levy R.
In reply
Archives of Family Medicine 1994;3:1035
HSL9178
Voltz K.
Implementing standard operating procedures: prescription for a successful pharmaceutical compliance program
Clinical Research and Regulatory Affairs 1994;11:(3-4):225-241
HSL9221
Axon SR.
Dispensing doctors-international perspective
Journal of Social and Administrative Pharmacy 1994;11:(3):106-111
HSL9224
Golodner LF.
Developing a patient focus: consumer perspective
Journal of Pharmaceutical Marketing Management 1994;8:(4):25-37
HSL9230
Basara LR.
Practical considerations when evaluating direct-to-consumer advertising as a marketing strategy for prescription medications
Drug Information Journal 1994;28:(2):461-470
HSL9231
Ukens C.
Generic industry "94: it's a jungle out there
Drug Topics 1994;138:6S, 8S, 10S-11S
HSL9232
Katz LM.
Nonprescription drug development
Drug Information Journal 1994;28:(2):449-451
HSL9234
Emmerton L, Benrimoj SI.
Factors influencing pharmacists' preferences for non-prescription cough suppressants
Journal of Social and Administrative Pharmacy 1994;11:(2):78-85
HSL9238
Engle RL.
Impact of a single-advertiser publication on physicians' perceptions and expected prescribing behavior
J Pharm Mark Manage 1994;8:(1):37-54
HSL9299
Duttagupta S, Aparasu RR, Desselle S, Das S.
Pharmacists' attitude toward direct-to-consumer advertising of prescription drugs
APhA Annual Meeting 1994;141:90
HSL12479
Scott LM.
Images in Advertising: The Need for a Theory of Visual Rhetoric
The Journal of Consumer Research 1994;21:(2):252-273
http://links.jstor.org/sici?sici=0093-5301(199409)21%3A2%3C252%3AIIATNF%3E2.0.CO%3B2-L
HSL15316
Denig P.
Drug choice in medical practice : rationales, routines and remedies
Geneeskunde Groningen: Rijksuniversiteit Groningen 1994
http://irs.ub.rug.nl/ppn/296349321
HSL5249
Ray WA, Griffin MR, Avorn J.
Evaluating drugs after their approval for clinical use.
N Engl J Med 1993 Dec 30;329:(27):2029-32
HSL5014
Inman WH, Pearce G.
Prescriber profile and postmarketing surveillance.
Lancet 1993 Dec 11;342:(8885):1491
HSL5171
Medawar C.
Drug information.
Lancet 1993 Dec 11;342:(8885):1490-1
HSL5710
Guidelines for pharmaceutical representatives
1993 Dec
HSL9312
Following suit
NARD J 1993 Dec;115:41-42
HSL9342
Cohen MR.
Voluntary error reporting to the USP/ISMP Medication Error Reporting Program
ASHP Midyear Clinical Meeting 1993 Dec;28:
HSL9343
Davenport SB, Garrison WO, O' NEAL, Seal BS.
Improving reimbursement of ambulatory prescriptions through indigent care programs by a multidisciplinary approach
ASHP Midyear Clinical Meeting 1993 Dec;28:
HSL9344
Smith MK, Gumbhir AK.
Perceptions of the 1987 Prescription Drug Marketing Act's impact on hospital pharmacy and drug distribution systems
ASHP Midyear Clinical Meeting 1993 Dec;28:
HSL9296
Scott L.
Merck-Medco merger boosts druggists' anger about pricing levels.
Mod Healthc 1993 Nov 29;23:(48):16
HSL5694
Merkel PA.
Inadvertent placement of an advertisement.
N Engl J Med 1993 Nov 25;329:(22):1661-2
HSL5709
Kassirer JP.
Inadvertent placement of an advertisement [Editor's reply]
New England Journal of Medicine 1993 Nov 251661-1662
HSL2157
Lexchin J.
Interactions between physicians and the pharmaceutical industry: what does the literature say?
CMAJ 1993 Nov 15;149:(10):1401-7
http://www.cmaj.ca/cgi/content/abstract/149/10/1401?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1=Lexchin+J&andorexactfulltext=and&searchid=1124491359271_2918&stored_search=&FIRSTINDEX=0&sortspec=relevance&resourcetype=1&journalcode=cmaj
Page 179 of 206 pages ‹ First < 177 178 179 180 181 > Last ›
